Johnson & Johnson’s single-injection coronavirus vaccine has started human trials


Johnson & Johnson’s investigational coronavirus vaccine entered human trials this month after an initial study showed it helped protect a group of primates with just one hit.According to a study published in the medical journal Nature, all animals that had been exposed to the pandemic six weeks after the injection were immunized except for one who had only low levels of the virus. The results prompted the healthcare company to start human trials last week in Belgium and earlier this week in the United States.

“We are delighted to see this preclinical data as it shows that our SARS-CoV-2 vaccine candidate generated a strong antibody response and provided protection with a single dose,” said Paul Stoffels, Scientific Director of Johnson & Johnson . “The results give us confidence as we progress in parallel in the development of our vaccines and in high-end manufacturing …”

The company said it plans to start the final phase of testing in September and have 1,045 people participate in the trial.

Johnson & Johnson competes with a number of other companies in the race for a vaccine, and while other companies have been faster in development, Johnson & Johnson’s ability to produce an immune response in one dose could give it an advantage in the deployment of a vaccine.

The company has not announced an expected price for its injection, but said it is ramping up manufacturing to try and deliver more than a billion doses to people around the world.


Please enter your comment!
Please enter your name here